BioMarin Acquiring Amicus -- Both Great Companies, Only One Worth Buying Now [Seeking Alpha]
BioMarin Pharmaceutical Inc. (BMRN)
Last biomarin pharmaceutical inc. earnings: 4/29 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.biomarin.com
Company Research
Source: Seeking Alpha
In fact, Amicus could potentially double its reach, going from 40 to 80 countries. I'm downgrading BMRN from Strong Buy to Buy. Voxzogo is decelerating from 20% to 15% Y/Y. Roctavian is slated for divestment. This acquisition will be revenue-accretive. I see 27% upside. DMX-200 is a compelling call option. If all goes well, it could render kidney transplants and dialysis obsolete for these patients. I'm rating FOLD as a Hold, due to its current valuation and the anchoring effect on the stock price following the BioMarin offer. quantic69/iStock via Getty Images On December 19th, BioMarin Pharmaceutical Inc. ( BMRN ) announced it is acquiring Amicus Therapeutics, Inc. ( FOLD ) at $14.50 per share. The transaction is expected to take effect in Q2 2026. This article covers both companies, but since This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such po
Show less
Read more
Impact Snapshot
Event Time:
BMRN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BMRN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BMRN alerts
High impacting BioMarin Pharmaceutical Inc. news events
Weekly update
A roundup of the hottest topics
BMRN
News
- Making U.S. biotech more competitive with China's could help rare disease patients, experts say [CNBC]CNBC
- Does BioMarin Pharmaceutical (BMRN) Price Weakness Contrast With Its Cash Flow Valuation? [Yahoo! Finance]Yahoo! Finance
- BMRN or TARS: Which Is the Better Value Stock Right Now? [Yahoo! Finance]Yahoo! Finance
- BioMarin Pharmaceutical touts $3.2B 2025 revenue, Voxzogo surge and Amicus deal at JPM Conference [Yahoo! Finance]Yahoo! Finance
- BioMarin Appoints Arpit Davé Chief Digital and Information Officer [Yahoo! Finance]Yahoo! Finance
BMRN
Earnings
- 10/27/25 - Miss
BMRN
Sec Filings
- 1/12/26 - Form 8-K
- 12/22/25 - Form 8-K
- 12/19/25 - Form 8-K
- BMRN's page on the SEC website